Deerfield Management Company

Deerfield Management Company

Deerfield Capital Management (DCM) is a global fixed-income investment adviser.

Company Overview

Deerfield Management Company, L.P. is an employee owned hedge fund sponsor. The firm primarily provides its services to pooled investment vehicles. Deerfield does structured financings for healthcare companies, particularly biotechs. Deerfield also conducts debt, secondary, IPO (initial public offering), and royalty financing.

History

Deerfield was established on January 13, 1994, by James Edward Flynn and is based in New York City.The firm is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1994. Deerfield is a large advisory firm with 14 clients and discretionary assets under management fund.

Deerfield launched in 1994 with $17 million in equity. Twenty years later, it manages funds in excess of $5 billion.

Investments

Deerfield has made 42 investments. One of their investments was on Jan 18, 2019, when they invested $8M in Itamar Medical. Deerfield has had 20 exits, including Foundation Medicine, Orchard Therapeutics, and Alector.

The firm invests in public equity markets of the United States. The firm makes its private equity investments in large-cap and growth companies. It typically invests in healthcare sector which includes pharmaceuticals, biotechnology, generic drugs, over the counter drugs, medical devices, medical equipment, diagnostics, hospital supplies, hospital services, acute care hospitals, nursing homes, psychiatric hospitals, alternate site providers, home care, physician practice management, medical software HMOs (health maintenance organization), health insurers, benefit management companies, distributors, drug stores, and animal healthcare products and services.

Timeline

January 18, 2019
Itamar Medical.

$8M

1994
Deerfield Management launched in 1994 with $17 million in equity.

Funded Companies

Company
Description
Industry
Website
Location
MetacrineSciences

A biotechnology company with a focus on pharmaceuticals that treat liver and gastrointestinal diseases. It was founded in 2014 and is located in San Diego, California.

Nkarta Therapeutics is a biotechnology company using natural killer (NK) immune cells for cellular therapies.

A genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases.

Cabaletta Bio is a biotechnology company developing cellular therapies for autoimmune disease.

RubiconMD is a New York-based company founded by Julien L. Pham, Gil Addo, Carlos Reines and Gilbert Addo.

A biopharmaceutical company focused on identifying cancer therapies

A pharmaceutical company developing protein degradation drugs to treat cancer and other diseases

A biopharmaceutical company dedicated to the development of novel therapeutics in the field of Epigenetics

Edgewise Therapeutics is a drug discovery and biotechnology company developing products based on the understanding of skeletal muscle.

Alector is a San Francisco-based biotechnology company.

A pharmaceutical company developing therapies for ocular diseases

REVOLUTION Medicines is a Redwood City, California-based company.

SentreHEART is a Redwood City, California-based healthcare company.

Mirum Pharmaceuticals is a Menlo Park, California-based company.

PQ Bypass is a medtech company advancing the treatment of long-segment peripheral artery disease.

TriNetX is a Cambridge, Massachusetts-based company.

CathWorks is an Israel-based company.

Generation Bio is a Cambridge, Massachusetts-based company.

Dracen Pharmaceuticals is a Baltimore-based company.

28 Results
Results per page:
Page 1 of 2

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 10, 2020
BioSpace
Boston Children's Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and Deerfield Management Company, a healthcare investment firm, announced a major research collaboration to advance promising therapeutics that will address unsolved medical needs and find cures for disease.
FinSMEs
June 2, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.